All sponsors

Celgene $BMY

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS20
PHASE 3 / 2-310
RECRUITING8
READOUTS ≤12 MONTHS7
READOUT SLIPPED >6 MO53%

Delay Index: of 19 active trials registered more than a year ago, 10 have moved their primary completion (readout) date by more than 6 months since first registration (median +8.2 months). See all sponsors →

Open Celgene on the live radar map → 📅 $BMY readout calendar (.ics)
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
AG-120
NCT02677922
P1/2Active, not recruitingLeukemia, Myeloid, Acute1302018-08-02 (-4 mo)
COMMANDS
NCT03682536
P3Active, not recruitingMyelodysplastic Syndromes3632023-03-31 (+24 mo)
CC-220
NCT02773030
P1/2Active, not recruitingMultiple Myeloma4662024-05-09 (+69 mo)
INDEPENDENCE
NCT04717414
P3Active, not recruitingMyeloproliferative Disorders; Myelofibrosis3132025-05-26 (+5 mo)
KarMMa-9
NCT06045806
P3Active, not recruitingMultiple Myeloma792025-08-11 (-67 mo)
GOLSEEK-2
NCT06425302
P2Active, not recruitingLymphoma, Follicular952026-06-19 (-5 mo)
CC-92480
NCT03989414
P1/2Active, not recruitingMultiple Myeloma4242026-11-30 (+52 mo)
SUCCESSOR-1
NCT05519085
P3RecruitingRelapsed or Refractory Multiple Myeloma8102027-01-10 (+14 mo)
CC-99282
NCT03930953
P1/2Active, not recruitingLymphoma, Non-Hodgkin4382027-04-07 (+35 mo)
MSS
NCT06782490
P2RecruitingMultiple Sclerosis Spasticity2002027-05-26 (+9 mo)
Elranatamab
NCT06988488
P1/2RecruitingMultiple Myeloma622027-05-31
GOLSEEK-1
NCT06356129
P3Active, not recruitingLarge B-cell Lymphoma8502027-08-09 (-12 mo)
rechARge
NCT06764485
P3Active, not recruitingMetastatic Castration-resistant Prostate Cancer9602027-09-12
EXCALIBER-RRMM
NCT04975997
P3Active, not recruitingMultiple Myeloma9392027-11-16 (+42 mo)
BMS-986368
NCT06808984
P2RecruitingAgitation; Alzheimer Disease1202027-11-26 (+8 mo)
ACE-536
NCT04143724
P2RecruitingBeta-Thalassemia992028-01-31 (+74 mo)
Golcadomide
NCT06911502
P3RecruitingFollicular Lymphoma4002028-04-24 (-27 mo)
Luspatercept
NCT04064060
P3RecruitingMyelodysplastic Syndromes (MDS); Beta-thalassemia6652028-05-12 (+4 mo)
TRANSCEND FL
NCT04245839
P2Active, not recruitingLymphoma, Non-Hodgkin2762031-09-30 (+107 mo)
Gene-modified (GM) T cell therapy
NCT03435796
P2/3RecruitingNeoplasms15412043-05-29